Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision T1D Platform
NCT07594145Phase 2Not yet recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of finerenone, sotagliflozin in type 1 diabetes mellitus (T1D), heart failure (HF), diabetic kidney disease (DKD), sponsored by Oregon Health & Science University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
finerenonesotagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)heart failure (HF)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT07594145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594145.